Related Experiment Video
Updated: Jul 8, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse
A G Reznikov1, L V Chaykovskaya, L I Polyakova
1VP Komisarenko Institute of Endocrinology and Metabolism, Academy of Medical Sciences of Ukraine, Kyiv, Ukraine. dccie@mail.kar.net
Unlabelled:
Endothelial monocyte-activating polypeptide-II (EMAP-II) is a novel proinflammatory cytokine with anti-angiogenic properties. The aim of this work was to evaluate in vivo antitumor activity of EMAP-II in growing human prostate adenocarcinoma xenograft mouse model.
Materials And Methods:
Recombinant human EMAP-II was expressed in Escherichia coli and purified after cleavage with enterokinase (EMAP-II e). EMAP-II preparations were injected to CBA mice bearing subrenal capsule xenografts of human prostate adenocarcinoma. After 3-days treatment, the xenografts were isolated and weighed, then the transplants exposed to EMAP II e (100 or 200 microg/kg b. w.) were examined histologically.
Results:
EMAP-II administered daily at a dose of 100 or 200 microg/kg b. w. caused striking retardation of local tumor progression as compared to the controls. Low dose (10 microg/kg) was effective in some cases.
Conclusion:
EMAP II exhibits significant antitumor activity in vivo in human prostate adenocarcinoma xenografts in mouse model.
